文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

耐药结核接触者含氟喹诺酮预防性治疗的社区可行性

Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen.
PubMed 文献 · Clin Infect Dis · 2020-01-01

215名符合条件者中172人(80.0%)启动治疗,121人(70.3%)完成治疗,12个月随访期间未观察到结核病或显著不良事件。结论认为该方案在高负担环境下可行且耐受良好。

要点

  • 耐药结核家庭接触者中符合条件的个体可启动含氟喹诺酮的6个月预防性治疗。
  • 研究中172/215(80.0%)启动治疗,121/172(70.3%)完成治疗。
  • 12个月随访期间未观察到结核病发病或显著不良事件。

核心结论

  • 含氟喹诺酮的预防性治疗方案在耐药结核接触者中可行且耐受良好。

研究设计与样本

  • 对儿童、有症状成人及免疫抑制者评估结核病;对无结核病的符合条件的接触者提供6个月氟喹诺酮治疗。

主要发现

  • 共筛查737人(92.1%),其中8人(1.1%)已在接受结核治疗,另3人(0.4%)诊断为结核病并开始治疗。
  • 215名符合感染治疗条件者中,172人(80.0%)启动治疗,121人(70.3%)完成治疗。
  • 12个月随访期间未观察到结核病发病或显著不良事件。

关键数值与推荐

  • 接触者中年龄<5岁、或5-17岁且结核菌素皮肤试验阳性或存在免疫抑制条件、或≥18岁且存在免疫抑制条件者,若无结核病则接受6个月氟喹诺酮治疗。

临床怎么用

  • 在高结核负担城市环境中,可考虑对耐药结核家庭接触者中的高危人群提供含氟喹诺酮的预防性治疗。
  • 实施时需进行家庭筛查、结核病评估,并监测治疗启动与完成情况。

局限性

  • 原文未明确报告研究设计类型(如前瞻性队列等)及样本量计算依据。
  • 原文未报告不良事件的具体定义或详细安全性评估方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies have demonstrated the effectiveness of a fluoroquinolone-based regimen to treat individuals presumed to be infected with drug-resistant tuberculosis (DR-TB). We sought to assess the feasibility of this approach in an urban setting in South Asia. METHODS: From February 2016 until March 2017, all household contacts of DR-TB patients enrolled at the Indus Hospital were screened for TB symptoms at home. Children aged 0-17 years, symptomatic adults, and those with an immunocompromising condition (human immunodeficiency virus, diabetes, or malnutrition) were evaluated for TB disease. Contacts diagnosed with TB disease were started on treatment. Contacts without TB disease aged <5 years, contacts aged between 5 and 17 years with either a positive tuberculin skin test or an immunocompromising condition, or contacts aged ≥18 years with an immunocompromising condition were offered 6 months of treatment with a fluoroquinolone. RESULTS: One hundred households with 800 contacts were enrolled: 353 (44.1%) individuals aged ≤17 years with a median age of 19 years (interquartile range, 10-32); 423 (52.9%) were males. In total, 737 (92.1%) individuals were screened, of which 8 were already on treatment for TB (1.1%); another 3 (0.4%) contacts were diagnosed with TB disease and started on treatment. Of 215 eligible for infection treatment, 172 (80.0%) contacts initiated and 121 (70.3%) completed treatment. No TB disease or significant adverse events were observed during 12 months of follow-up. CONCLUSIONS: Fluoroquinolone-based treatment for contacts with presumed DR-TB infection is feasible and well tolerated in a high TB burden setting.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Malik AA, Fuad J, Siddiqui S, et al. Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen. Clin Infect Dis. 2020. PMID: 31190072. doi:10.1093/cid/ciz502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。